Clearside Biomedical, Inc. CLSD
We take great care to ensure that the data presented and summarized in this overview for Clearside Biomedical, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding CLSD
View all-
Vanguard Group Inc Valley Forge, PA2.81MShares$2.44 Million0.0% of portfolio
-
Act Capital Management, LLC Wayne, PA2.2MShares$1.91 Million3.43% of portfolio
-
Carmignac Gestion Paris, I01.93MShares$1.68 Million0.03% of portfolio
-
Black Rock Inc. New York, NY798KShares$694,3790.0% of portfolio
-
Geode Capital Management, LLC Boston, MA764KShares$664,7300.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny722KShares$627,9560.0% of portfolio
-
First Manhattan CO New York, NY406KShares$352,9310.0% of portfolio
-
State Street Corp Boston, MA265KShares$230,7780.0% of portfolio
-
Bridgeway Capital Management, LLC Houston, TX255KShares$221,8500.01% of portfolio
-
Northern Trust Corp Chicago, IL165KShares$143,9840.0% of portfolio
Latest Institutional Activity in CLSD
Top Purchases
Top Sells
About CLSD
Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase 1/2a clinical trial; and CLS-301, an integrin inhibitor suspension for the treatment of diabetic macular edema and macular degeneration. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.
Insider Transactions at CLSD
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 24
2025
|
Clay Thorp |
BUY
Open market or private purchase
|
Direct |
15,000
+7.85%
|
$0
$0.92 P/Share
|
|
Nov 01
2024
|
Ngai Hang Victor Chong Chief Medical Officer |
BUY
Open market or private purchase
|
Direct |
36,500
+26.74%
|
$36,500
$1.0 P/Share
|
|
Jun 24
2024
|
Ngai Hang Victor Chong Chief Medical Officer |
BUY
Open market or private purchase
|
Direct |
23,500
+27.01%
|
$23,500
$1.06 P/Share
|
|
May 15
2024
|
Benjamin R Yerxa |
BUY
Open market or private purchase
|
Direct |
7,813
+30.32%
|
$7,813
$1.31 P/Share
|
|
Apr 18
2024
|
Anthony S Gibney |
BUY
Open market or private purchase
|
Direct |
93,290
+48.26%
|
$93,290
$1.3 P/Share
|
|
Apr 17
2024
|
Anthony S Gibney |
BUY
Open market or private purchase
|
Direct |
6,710
+50.0%
|
$6,710
$1.25 P/Share
|
|
Mar 20
2024
|
Ngai Hang Victor Chong Chief Medical Officer |
BUY
Open market or private purchase
|
Direct |
30,000
+50.0%
|
$30,000
$1.6 P/Share
|
|
Feb 07
2024
|
Bradford T Whitmore > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
444,444
+9.0%
|
$444,444
$1.35 P/Share
|
|
Jan 19
2024
|
Charles A. Deignan Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
12,900
-3.24%
|
$12,900
$1.28 P/Share
|
|
Jan 19
2024
|
George M Lasezkay CEO |
SELL
Open market or private sale
|
Direct |
18,000
-3.71%
|
$18,000
$1.27 P/Share
|
|
Nov 01
2023
|
Bradford T Whitmore > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
64,366
+1.56%
|
$0
$0.74 P/Share
|
|
Oct 31
2023
|
Bradford T Whitmore > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
70,812
+1.75%
|
$0
$0.73 P/Share
|
|
Oct 30
2023
|
Bradford T Whitmore > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
600
+0.02%
|
$0
$0.68 P/Share
|
|
Oct 03
2023
|
Nancy J Hutson |
BUY
Open market or private purchase
|
Direct |
10,000
+9.71%
|
$0
$0.86 P/Share
|
|
Sep 25
2023
|
Clay Thorp |
BUY
Open market or private purchase
|
Direct |
10,000
+19.79%
|
$0
$0.86 P/Share
|
|
Sep 22
2023
|
William D. Humphries |
BUY
Exercise of conversion of derivative security
|
Direct |
22,727
+30.81%
|
$0
$0.4 P/Share
|
|
Sep 13
2023
|
Charles A. Deignan Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
34,090
+7.9%
|
$0
$0.4 P/Share
|
|
Jan 20
2023
|
Thomas Ciulla Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
13,700
-4.48%
|
$13,700
$1.47 P/Share
|
|
Jan 19
2023
|
George M Lasezkay CEO |
SELL
Open market or private sale
|
Direct |
20,030
-3.97%
|
$20,030
$1.46 P/Share
|
|
Jan 19
2023
|
Charles A. Deignan Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
14,030
-3.72%
|
$14,030
$1.5 P/Share
|
Last 12 Months Summary
| Open market or private purchase | 82.8K shares |
|---|